Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

82.49 -3.49 (-4.06%)
Official Closing Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
1 Profitable Stock to Consider Right Now and 2 to Think Twice About
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
3 Absurdly Cheap Stocks Ready for a Breakout
All three stocks are poised to go higher. 
Via The Motley Fool
RFK Jr's CDC Panel Recommends Merck's RSV Shot For Infants
CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials. 
Via Benzinga
CDC Vaccine Panel Overhauled by RFK Jr. Votes To Drop Mercury Preservative, Critics Sound Alarm
The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection. 
Via Stocktwits
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
Elanco upgraded to Outperform by William Blair as pipeline gains traction and EMA backs Zenrelia ahead of expected Q3 approval. 
Via Benzinga
ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
2 Stocks Too Cheap to Ignore at These Prices
Via The Motley Fool
Topics Artificial Intelligence Lawsuit
RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group
Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts. 
Via Benzinga
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention
From Merck & Co., Inc.
Via Business Wire
Merck's Hypertension Drug Cuts Clinical Worsening Risk In Over 70% Of Patients On Double Background Therapy
Merck's Winrevair reduced clinical worsening in PAH patients in the Phase 3 HYPERION trial, building on prior positive study outcomes. 
Via Benzinga
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere
The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs. 
Via Benzinga
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices. 
Via Benzinga
2 Reasons to Watch MRK and 1 to Stay Cautious
Shareholders of Merck would probably like to forget the past six months even happened. The stock dropped 20.3% and now trades at $79.30. This might have investors contemplating their next move. 
Via StockStory
Topics Supply Chain
Nobody Wants To Touch Healthcare Stocks Now – That Might Be A Big Mistake
Healthcare stocks are lagging the market by the widest margin since 2008. Analysts and valuation trends point to a rebound. 
Via Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Dividend Stock with Solid Fundamentals
MERCK & CO. (NYSE:MRK) is a top dividend stock with a 3.96% yield, strong profitability, and solid financial health, making it a compelling choice for income investors. 
Via Chartmill
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
2 Dividend Stocks to Buy and Never Sell
Via The Motley Fool
Topics Lawsuit
3 Mega-Cap Stocks with Competitive Advantages
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their... 
Via StockStory
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such... 
Via Stocktwits
Topics Government
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
The Dow Jones index could have fared better in May if not for these two stocks. 
Via The Motley Fool
Topics Government Intellectual Property Lawsuit
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial. 
Via Benzinga
Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish
In the U.S., it is estimated there will be approximately 72,680 new cases of head and neck cancer diagnosed and more than 16,680 deaths from the disease in 2025, Merck said. 
Via Stocktwits
Topics Death
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
From Merck & Co., Inc.
Via Business Wire
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
From Merck & Co., Inc.
Via Business Wire
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit
Martin Kulldorff, appointed by RFK Jr. to a federal vaccine panel, previously earned $33K as an expert witness in lawsuits targeting Merck's Gardasil vaccine. 
Via Benzinga
Topics Lawsuit
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.